Axogen Completes Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft Page 1

ALACHUA, Fla. and TAMPA, Fla., Sept. 6, 2024 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in the development and marketing of innovative surgical solutions for peripheral nerve injuries, announced that it has completed the ongoing submission process for its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft.

“I am proud of the significant progress our team has made in transitioning Avance from a tissue to a biologic,” said Michael Dale, CEO and President of Axogen, Inc. “We will continue to work closely with the FDA as they review our application.”